06 May, 2024 Will the PTO's Proposed Expansion of Filing Settlement Agreements Help to Reduce Drug Prices? By Chad Landmon Craig Minerva In a recent Federal Register notice, the PTO announced a proposed rule requiring that any settlement agreement resolving a PTAB...
27 Mar, 2024 Puma and the Pitfalls of the “Narrow” Exclusive License By Ted Mathias Matt Murphy Puma Biotechnology is the latest victim of standing requirements in patent cases that continue to wreak havoc on plaintiffs’ ability to...
25 Mar, 2024 More Lessons from Mumbai – Reflections on a Hatch-Waxman and PIV Litigation Panel Discussion By Chad Landmon Reflecting back on our time at the 13th Annual Pharma IPR Conference in Mumbai, there was a lively discussion during the panel that I...
18 Mar, 2024 Going Global on Polymorphs By Ted Mathias Aziz Burgy Rebecca Clegg We were so pleased to have the opportunity to address InformaMarkets’ 13th Annual Pharma IPR Conference in Mumbai on legal challenges to...
11 Mar, 2024 Reconnecting in Mumbai at the 2024 Pharma IPR Conference By Chad Landmon Aziz Burgy Ted Mathias Rebecca Clegg +1 more... Show less We just returned from a weeklong trip to Mumbai in which Axinn served as the Platinum sponsor of InformaMarkets 13th Annual Pharma IPR...
23 Feb, 2024 One Down, Eight to Go: Texas Judge Dismisses Medicare Drug Price Case – Will Others Follow? By Chad Landmon Gulrukh Haroon A domino has fallen, but the question remains whether there are more to come. On February 12, 2024, the U.S. District Court for the...
16 Feb, 2024 Happy 40th Hatch-Waxman! By Chad Landmon Turning 40 is a big milestone for most of us. When I turned 40 – I won't tell you how long ago that was – I was knee-deep in Paragraph IV...
16 Feb, 2024 Pharma IPR Conference By Aziz Burgy Rebecca Clegg Chad Landmon Ted Mathias +1 more... Show less Axinn is proud to be a Platinum Partner of the Pharma IPR Conference On March 5 at 11:00 AM, partners Aziz Burgy, Ted Mathias, and...
14 Feb, 2024 Bayer Covenants Not to Sue, Still Has Headache By Ted Mathias Bayer's ‘053 patent on its drug Xarelto® expires in November 2024, and Bayer granted Mylan a covenant not to sue. Bayer has a second...
13 Feb, 2024 CREATing Controversy: Can a Brand Manufacturer Deny Sample Requests? By Chad Landmon Ian Swan Can a drug manufacturer refuse to provide samples of its innovator product under the CREATES Act if it thinks that the requester will not...
09 Feb, 2024 Will India Replace China in the U.S. Drug Supply Chain? By Chad Landmon In a recent opinion piece in Newsweek, Dr. Rahul Tiwari asserts that pharmaceutical companies in India have an opportunity to supplant...
29 Jan, 2024 Opening Another Front in the Brand/Generic Battle? By Chad Landmon Although it's not often that I read a decision by the U.S. Court of Federal Claims, it appears that Vanda may be opening a new front in...
17 Jan, 2024 Ready for the Flood of Litigation Against Federal Agencies? By Chad Landmon Aaron Savit Ian Swan Today, the Supreme Court heard oral arguments in two related cases that may have a significant impact on litigation against federal...
18 Dec, 2023 Crossing the Blurred Line Between Brands and Generics By Aziz Burgy Ian Swan Clients often ask if a law firm can represent both brand and generic drug manufacturers. It’s a reasonable question, particularly when...
14 Dec, 2023 FTC Spoke, Kaleo and Impax Listened: Orange Book Patent Delistings Begin By Chad Landmon Ross Blau As discussed last month, the FTC sent letters to 10 pharmaceutical companies, asserting that their listing of over 100 patents in FDA’s...
11 Dec, 2023 The Skinny on Infringement of Method of Treatment Claims By Rebecca Clegg In Hatch-Waxman litigation, method of treatment patents present unique infringement issues. Because generic drug manufacturers typically...